TICKERNERD
Menu
QGENQGENHealthcare · Diagnostics & Research

QGEN Stock Forecast: Qiagen NV Price Predictions for 2026-2027

Last close, 7 Oct 2026
$45
−1.88% on the day

The 16 Wall Street analysts covering Qiagen NV hold a median 12-month price target of $47 — +4.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 67 of 100 as at 7 Oct 2026 — in the upper half.

Market cap
$9.4B
Ticker Nerd rank
67 / 100
Median analyst target
$47
Analysts covering
16
Revenue$535.0M+0.3% y/y
Operating income$140.8M
Net income$103.4M
Free cash flow$157.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.4%
1M
+3.0%
YTD
−4.5%
1Y
−3.4%
From 52W high
−18.8%
From 52W low
+38.5%
$32
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QGEN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Qiagen NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Oct 2026
67 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
97
Volatility
97
Quality
78
Revisions
64
Accruals
57
Growth
50
Momentum
44
Issuance
40
Size
16

Value (97): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (40): The company has been issuing shares or taking on financing, diluting existing holders.

Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QGEN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QGEN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$30$35$40$45$50$55Jan 26Apr 26Jul 26Oct 26QGENHigh $55Median $47Low $40

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says16 analysts
9 Buy7 Hold0 Sell
Low $40Median $47High $55

The green dot is the last close — the median target sits +4.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
6 Oct 2026BarclaysUpgradeOverweight$40 → $55
9 Sept 2026UBSMaintainsNeutral$52 → $47
10 Aug 2026CitigroupMaintainsNeutral$38 → $45
10 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026BarclaysMaintainsEqual-Weight—
7 Aug 2026BarclaysMaintainsEqual-Weight$38 → $40
7 Aug 2026JP MorganMaintainsOverweight$45 → $50
7 Aug 2026JP MorganMaintainsOverweight—
23 June 2026Morgan StanleyUpgradeOverweight$40 → $42
23 June 2026Morgan StanleyUpgradeOverweight—
18 May 2026StifelMaintainsHold—
7 May 2026TD CowenMaintainsHold—
29 Apr 2026BairdUpgradeOutperform—
29 Apr 2026BarclaysMaintainsEqual-Weight—
29 Apr 2026CitigroupMaintainsNeutral—
29 Apr 2026JP MorganMaintainsOverweight—
14 Apr 2026BarclaysDowngradeEqual-Weight—
13 Mar 2026Deutsche BankUpgradeBuy—
6 Feb 2026CitigroupMaintainsNeutral—
6 Feb 2026JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QGEN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

QGEN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 7 Oct 2026, Qiagen NV returned −3.4% against +17.4% for the S&P 500, dividends included.

QGEN vs S&P 500, last 12 monthsTotal return, rebased to 100
708090100110120Jan 26Apr 26Jul 26Oct 26QGENS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

QGEN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.4%
Analysts raising
4
Analysts cutting
2
Fundamentals

Qiagen NV (QGEN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
23.0×

Cheaper than 32% of US stocks

Price / sales
4.5×

Cheaper than 27% of US stocks

Price / book
2.8×

Cheaper than 34% of US stocks

EV / EBITDA
14.0×

Cheaper than 25% of US stocks

Growth & margins
Revenue growth (YoY)
0.3%

Higher than 28% of US stocks

Earnings growth (YoY)
7.4%

Higher than 44% of US stocks

Gross margin
63.6%

Higher than 77% of US stocks

Operating margin
26.3%

Higher than 85% of US stocks

Net margin
19.5%

Higher than 82% of US stocks

Returns & dividend
Return on equity
11.9%

Higher than 68% of US stocks

Return on assets
5.9%

Higher than 81% of US stocks

Dividend yield
0.8%

Higher than 68% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Qiagen NV (QGEN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Qiagen NV has a market value of $9.4B and an enterprise value of $10.3B.

  • Revenue in the twelve months to 30 June 2026: $2.1B. The latest quarter grew 0.3% year on year.

  • Net income over the same four quarters: $409.3M, a 19.5% net margin.

  • Diluted earnings per share, trailing twelve months: $1.98.

  • Free cash flow in the twelve months to 30 June 2026: $440.6M.

  • Shares outstanding: 206.5M.

  • Trailing P/E: 23.0×; forward P/E: 17.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.76%, paying out 18% of earnings.

  • Qiagen NV employs 5,500 people — $382K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

QGEN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
QGENQiagen NV$9.4B
67
ICLRIcon PLC$12.5B
71
GRALGRAIL, Inc.$5.9B
38
CRLCharles River Laboratories International, Inc.$14.8B
85
RDNTRadNet, Inc.$5.3B
36
SHCSotera Health Co.$5.1B
97
RVTYRevvity, Inc.$17.1B
94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Qiagen NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QGEN news & analysis

QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery

Business Wire · 6 Oct 2026positive

QIAGEN announced new AI capabilities for analyzing biological and genomic data, including IPA Investigator for Ingenuity Pathway Analysis and the QIAGEN Discovery Platform. The tools are designed to help researchers analyze data faster while keeping supporting scientific evidence visible.

Why it matters — The announcement expands QIAGEN’s bioinformatics offerings for research and drug discovery.

QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel

Zacks Investment Research · 2 Oct 2026positive

QIAGEN expanded its U.S. QIAstat-Dx portfolio with a newly FDA-cleared panel that detects gram-negative bacteria and resistance markers in about one hour.

Why it matters — This expands QIAGEN's U.S. diagnostic product offerings and strengthens its position in rapid molecular testing.

QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection Panel

Business Wire · 28 Sept 2026positive

QIAGEN announced that the U.S. FDA cleared a new QIAstat-Dx panel that detects gram-negative bacteria and antibiotic resistance markers in about one hour. This clearance completes the company's U.S. QIAstat-Dx bloodstream infection portfolio, complementing the previously cleared gram-positive bacteria and fungi panel.

Why it matters — Completion of the full U.S. QIAstat-Dx bloodstream infection portfolio expands QIAGEN's available diagnostic offering for U.S. laboratories.

QIAGEN Launches QIAmini to Automate Small-Batch Sample Preparation

Business Wire · 24 Sept 2026positive

QIAGEN N.V. announced the launch of QIAmini, a compact automated sample preparation system aimed at research laboratories and academic customers processing smaller sample batches. The system is positioned as a time-saving and cost-efficient alternative to manual sample processing for labs that do not require larger automated systems.

Why it matters — QGEN watchers would care because the launch expands QIAGEN's product portfolio into the small-batch and academic research segment, potentially broadening its customer base beyond users of larger automated systems.

Here's Why You Should Hold QIAGEN Stock in Your Portfolio for Now

Zacks Investment Research · 24 Sept 2026neutral

Zacks recommends holding QIAGEN (QGEN) stock for now, citing its test menu expansion and strategic partnerships as growth drivers, while noting that cautious spending and competition could limit near-term gains.

Why it matters — QGEN watchers would care because the piece balances growth catalysts against headwinds that may affect the company's near-term performance.

FAQ

Frequently asked questions about QGEN stock

What is the QGEN stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Qiagen NV have a median 12-month price target of $47, with estimates ranging from $40 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QGEN stock a buy right now?

Of the 16 analysts covering Qiagen NV, 9 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Qiagen NV 67 out of 100 across roughly 4,600 US stocks as at 7 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QGEN?

As at 7 Oct 2026, Qiagen NV ranks 67 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (97 of 100).

Will QGEN stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies +4.9% from the last close, and Ticker Nerd's factor model ranks Qiagen NV 67 out of 100 as at 7 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QGEN stock forecast for 2030?

No analyst covering Qiagen NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QGEN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $55 over the next 12 months.

How has QGEN stock performed over the past year?

Qiagen NV returned -3.4% over the 12 months to 7 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Qiagen NV do?

Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research.

What is the latest news on QGEN?

The most recent item we track (Business Wire, 6 Oct 2026): "QIAGEN Expands AI-Powered Bioinformatics for Research and Drug Discovery". QIAGEN announced new AI capabilities for analyzing biological and genomic data, including IPA Investigator for Ingenuity Pathway Analysis and the QIAGEN Discovery Platform. The tools are designed to help researchers analyze data faster while keeping supporting scientific evidence visible.

Company

About Qiagen NV.

Qiagen N.V. is a biotechnology company that provides Sample to Insight solutions for molecular diagnostics, applied testing, academic research, and pharmaceutical research. Qiagen develops and markets sample preparation products, assay technologies, instruments, and bioinformatics software that help customers isolate, process, and analyze DNA, RNA, and proteins from biological materials. Its portfolio supports workflows in areas such as genotyping, gene expression, viral and bacterial analysis, next-generation sequencing, forensic testing, and clinical decision support. The company serves laboratories, healthcare organizations, research institutions, and life science companies worldwide, making it a key supplier in molecular testing and research workflows. Qiagen N.V. is headquartered in Venlo, the Netherlands, with major operational activities in Hilden, Germany.

CEO Mr. Jonathan M. Pratt · 5,500 employees · Netherlands · https://www.qiagen.com